• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectis S.A. - American Depositary Shares (NQ:CLLS)

    2.900 -0.090 (-3.01%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cellectis S.A. - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Provides Full Report for Second Quarter 2023 Financial Results
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Recap: Cellectis Q1 Earnings ↗
     
    Via Benzinga
    News headline image
    Expert Ratings for Cellectis ↗
     
    Via Benzinga
    News headline image
    A Preview Of Cellectis's Earnings ↗
     
    Via Benzinga
    News headline image
    Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
    BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population 
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For March 8, 2023 ↗
    Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
    Via Benzinga
    News headline image
    Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    There's a Lot of Upside For Emerging Gene-Editing Companies
    These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
    Via MarketBeat
    News headline image
    Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.